238 related articles for article (PubMed ID: 27713134)
1. A three ion channel genes-based signature predicts prognosis of primary glioblastoma patients and reveals a chemotherapy sensitive subtype.
Wang HY; Li JY; Liu X; Yan XY; Wang W; Wu F; Liang TY; Yang F; Hu HM; Mao HX; Liu YW; Zhang SZ
Oncotarget; 2016 Nov; 7(46):74895-74903. PubMed ID: 27713134
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of ion channel genes in Chinese patients with gliomas based on mRNA expression profiling.
Lu FF; Wang HY; He XZ; Liang TY; Wang W; Hu HM; Wu F; Liu YW; Zhang SZ
J Neurooncol; 2017 Sep; 134(2):397-405. PubMed ID: 28752501
[TBL] [Abstract][Full Text] [Related]
3. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
4. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
5. Genetic and clinical characteristics of primary and secondary glioblastoma is associated with differential molecular subtype distribution.
Li R; Li H; Yan W; Yang P; Bao Z; Zhang C; Jiang T; You Y
Oncotarget; 2015 Mar; 6(9):7318-24. PubMed ID: 25821160
[TBL] [Abstract][Full Text] [Related]
6. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
7. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.
Niyazi M; Pitea A; Mittelbronn M; Steinbach J; Sticht C; Zehentmayr F; Piehlmaier D; Zitzelsberger H; Ganswindt U; Rödel C; Lauber K; Belka C; Unger K
Oncotarget; 2016 Jul; 7(29):45764-45775. PubMed ID: 27302927
[TBL] [Abstract][Full Text] [Related]
8. Identification of a DNA Repair-Related Multigene Signature as a Novel Prognostic Predictor of Glioblastoma.
Jin S; Qian Z; Liang T; Liang J; Yang F; Sun L; Li W; Qiu X; Zhang M
World Neurosurg; 2018 Sep; 117():e34-e41. PubMed ID: 29807183
[TBL] [Abstract][Full Text] [Related]
9. Ion channel gene expression predicts survival in glioma patients.
Wang R; Gurguis CI; Gu W; Ko EA; Lim I; Bang H; Zhou T; Ko JH
Sci Rep; 2015 Aug; 5():11593. PubMed ID: 26235283
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
11. A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
Fatai AA; Gamieldien J
BMC Cancer; 2018 Apr; 18(1):377. PubMed ID: 29614978
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential biomarkers related to glioma survival by gene expression profile analysis.
Hsu JB; Chang TH; Lee GA; Lee TY; Chen CY
BMC Med Genomics; 2019 Mar; 11(Suppl 7):34. PubMed ID: 30894197
[TBL] [Abstract][Full Text] [Related]
13. A signature based on survival-related genes identifies high-risk glioblastomas harboring immunosuppressive and aggressive ECM characteristics.
Chen D; Chen D; Cao D; Hu J; Yao Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):368-382. PubMed ID: 29774872
[TBL] [Abstract][Full Text] [Related]
14. Angiogenin Upregulation Independently Predicts Unfavorable Overall Survival in Proneural Subtype of Glioblastoma.
Hu JL; Luo WJ; Wang H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819846636. PubMed ID: 31072237
[TBL] [Abstract][Full Text] [Related]
15. Ion channel expression patterns in glioblastoma stem cells with functional and therapeutic implications for malignancy.
Pollak J; Rai KG; Funk CC; Arora S; Lee E; Zhu J; Price ND; Paddison PJ; Ramirez JM; Rostomily RC
PLoS One; 2017; 12(3):e0172884. PubMed ID: 28264064
[TBL] [Abstract][Full Text] [Related]
16. A robust two-gene signature for glioblastoma survival prediction.
Pan Y; Zhang JH; Zhao L; Guo JC; Wang S; Zhao Y; Tao S; Wang H; Zhu YB
J Cell Biochem; 2020 Jul; 121(7):3593-3605. PubMed ID: 31960992
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
18. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma.
Wang W; Zhang L; Wang Z; Yang F; Wang H; Liang T; Wu F; Lan Q; Wang J; Zhao J
Oncotarget; 2016 Oct; 7(43):69991-69999. PubMed ID: 27588397
[TBL] [Abstract][Full Text] [Related]
19. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
20. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]